Pharmaceutical - Mergers & Acquisitions, Roche


Popular Filters

Global oncology market to hit $109 billion in 2020

Global oncology market to hit $109 billion in 2020


Cancer, with a death toll exceeding that of AIDS (acquired immune deficiency syndrome), tuberculosis…

AvastinCelgene Corp.GlobalMarkets & MarketingMergers & AcquisitionsNovartisOncologyPharmaceuticalResearchRevlimidRoche

Roche makes another acquisition, paying $8.3 billion for InterMune

Roche makes another acquisition, paying $8.3 billion for InterMune


Announcing its fourth acquisition this year, Swiss pharma major Roche said on Sunday that it has entered…

EsbrietInterMuneMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoche

Roche said to be eyeing full control of Chugai

Roche said to be eyeing full control of Chugai


Although the Swiss drug major has not issued a confirmation, media reports say Roche is close to acquiring…

Business FinanceChugai PharmaceuticalChugai Pharmaceutical Co.Chugai PharmaceuticalsHoffmann-La RocheInvestmentMergers & AcquisitionsPharmaceuticalRoche

Roche partners in new company for MS research

Roche partners in new company for MS research


Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

Roche to acquire Genia Technologies for up to $350 million

Roche to acquire Genia Technologies for up to $350 million


Swiss drug major Roche said this morning that it plans to acquire Genia Technologies, a privately held…

Genia TechnologiesMergers & AcquisitionsPharmaceuticalRoche

Report: Life science companies experience IPO slowdown


Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

July a strong month for life sciences IPOs and M&A


The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Amylin said to be attracting several Big Pharma suitors


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Roche will not extend its tender offer for Illumina


In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ratchets up the pressure on Illumina; analytical view


If there is an axiom to describe Swiss drug major Roche (ROG: SIX), it is that what Roche wants, it gets,…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche presses on with takeover, despite further rejection by Illumina board


Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis


There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid


Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net…

AlkermesElanElan Drug TechnologiesFinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche has options beyond Illumina


Speaking at the companys annual meeting, Swiss drug maj'or Roche (ROG: SIX) chairman Franz Humer said:…

FinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche extends Illumina takeover deadline


Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina…

HomeIlluminaMergers & AcquisitionsPharmaceuticalRoche

Riemser strengthens oncology range with Roche drug


German drugmaker Riemser Arzneimittel AG is extending its range of supportive cancer therapy products…

Mergers & AcquisitionsOncologyOstacPharmaceuticalRiemser ArztneimittelRoche

Illumina board says Roche hostile bid “grossly inadequate”


Having thoroughly reviewed Swiss drug and diagnostics major Roche’s (ROG: SIX) hostile takeover…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Illumina implements “poison pill” with regard to Roche bid


Responding to Swiss drug major Roche’s (ROG: SIX) hostile takeover over offer of $44.50 per share…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche makes $5.7 billion hostile bid for Illumina


Swiss drugs and diagnostic major Roche (ROG: SIX) announced this morning that it is proposing to acquire…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche in epigenetics drug discovery collaboration


USA-based Constellation Pharmaceuticals says that it has entered into a major strategic agreement with…

BiotechnologyConstellation PharmaceuticalsGenentechLicensingMergers & AcquisitionsOncologyPharmaceuticalRoche

Back to top